DexTech's Phase IIb study for OsteoDex concludes with positive follow-up results

The company's Phase IIb study for the treatment of skeletal metastatic castration-resistant prostate cancer (mCRPC) shows continued promising follow-up data and confirms previously announced partial results.

Formalities in the form of closing the study database (database base lock) and signing of follow-up forms (eCRFs) have been delayed somewhat as a result of the ongoing virus pandemic. The study's final results, including 2-year survival data, will be presented, together with the company's and CEO's comments, in the form of a press release in June.

For additional information:

Gösta Lundgren - CFO & Investor Relations

DexTech Medical AB

Telephone: +46 (0) 707104788

E-mail: gosta.lundgren@dextechmedical.com

This information is information that Dextech Medical AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, on May 28, 2020.

DexTech Medical AB is a Swedish research company that, based on its technology platform, has developed four drug candidates that are protected by patents. The main candidate is OsteoDex for the treatment of castration-resistant prostate cancer (CRPC) with skeletal metastases. A successful Phase II clinical study has been conducted with OsteoDex where the result shows high tolerability with mild side effects as well as efficacy and treatment effect on patients who fail on existing drugs. DexTech's goal is to, after completing a phase II study, license each drug candidate. DexTech Medical AB is listed on the Spotlight Stock Market.